Orally active angiotensin-converting enzyme inhibitor (SO 14,225) as a treatment for essential hypertension
Détails
ID Serval
serval:BIB_D9D82C821BCE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Orally active angiotensin-converting enzyme inhibitor (SO 14,225) as a treatment for essential hypertension
Périodique
British Journal of Clinical Pharmacology
ISSN
0306-5251
Statut éditorial
Publié
Date de publication
1979
Peer-reviewed
Oui
Volume
7 Suppl 2
Pages
205S-211S
Langue
anglais
Notes
Journal Article
Résumé
1 Captopril (SQ14,225), an orally active inhibitor of angiotensin-converting enzyme, was administered to nine patients with essential hypertension. Plasma renin activity (PRA) was low in four, 'normal' in three and high in two patients. 2 In the hospital, captopril alone induced a significant drop in BP from 165 +/- 6/106 +/- 2 to 140 +/- 5/90 +/- 1 mmHb (P less than 0.001). PRA increased concomitantly (P less than 0.05), whereas plasma-converting enzyme activity (P less than 0.005) and plasma aldosterone (P less than 0.05) were reduced. 3 Six patients underwent chronic ambulatory therapy with captopril for a mean of 16 +/- 3 weeks. After discharge from the hospital, BP remained normalized but in five out of six patients this required additional diuretic therapy. 4 The results suggest that captopril alone or combined with diuretic therapy provides a new, efficient and well tolerated tool to treat patients with essential hypertension independently of their PRA level. It may turn out to be more effective in lowering BP than beta-adrenoceptor-blocking agents.
Mots-clé
AdultAldosterone/blood*Angiotensin-Converting Enzyme InhibitorsBlood Pressure/drug effectsFemaleHumansHypertension/*drug therapyMaleMiddle AgedProline/*analogs & derivatives/therapeutic useRenin/blood
Pubmed
Web of science
Création de la notice
06/03/2009 13:00
Dernière modification de la notice
20/08/2019 16:59